scholarly journals Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

2004 ◽  
Vol 8 (45) ◽  
Author(s):  
E Warren ◽  
E Weatherley-Jones ◽  
J Chilcott ◽  
C Beverley
Keyword(s):  
Systematic Review ◽  
Economic Evaluation ◽  
Insulin Glargine ◽  
Insulin Analogue ◽  
Analogue Insulin ◽  
Acting Insulin ◽  
Long Acting

Insulin glargine: A systematic review of a long-acting insulin analogue

2003 ◽  
Vol 25 (6) ◽  
pp. 1541-1577 ◽  
Author(s):  
Fei Wang ◽  
Jana M. Carabino ◽  
Cunegundo M. Vergara
Keyword(s):  
Systematic Review ◽  
Insulin Glargine ◽  
Insulin Analogue ◽  
Acting Insulin ◽  
Long Acting

A new generation ultra-long-acting insulin analogue-insulin degludec

2013 ◽  
Vol 13 (1) ◽  
pp. 6-8
Author(s):  
YuPu HUANG ◽  
Qin ZHANG ◽  
LanXin WANG ◽  
Wei CHEN
Keyword(s):  
Insulin Analogue ◽  
Insulin Degludec ◽  
Analogue Insulin ◽  
Acting Insulin ◽  
Long Acting ◽  
New Generation

scholarly journals Insulin degludec is a new ultra-long-acting insulin analogue

2014 ◽  
Vol 17 (2) ◽  
pp. 91-104 ◽  
Author(s):  
Ivan Ivanovich Dedov ◽  
Marina Vladimirovna Shestakova
Keyword(s):  
Glycemic Control ◽  
Insulin Glargine ◽  
Insulin Analogue ◽  
Insulin Analogues ◽  
Insulin Degludec ◽  
Treat To Target ◽  
Nocturnal Hypoglycaemia ◽  
Acting Insulin ◽  
Long Acting

Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia as compared to NPH insulin. However, fear of hypoglycaemia and weight gain, as well as the complexity of regimen, are still the most important barriers to well-timed initiation and intensification of insulin therapy. Insulin degludec (Tresiba?) is a new ultra-long-acting insulin analogue. After subcutaneous injection degludec forms repository of soluble multi-hexamers, which are gradually absorbed to the bloodstream, providing a flat, stable antihyperglycemic effect lasting more than 42 h, and low intra-individual variability as opposed to currently used basal insulin analogues, insulin glargine and insulin detemir. In the seven randomized, open label, controlled phase 3 trials lasting 26 or 52 weeks, using treat-to-target (no more) non-inferiority design, insulin degludec provided glycemic control similar to that of insulin glargine with lower risk of nocturnal hypoglycaemia and good safety profile in patients with type 1 or 2 diabetes. Furthermore, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes have shown that it is possible to vary the injection time without compromising glycemic control or safety of the therapy.

Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes. A systematic review and meta-analysis

2011 ◽  
Vol 121 (7-8) ◽  
pp. 237-246 ◽  
Author(s):  
Agnieszka Szypowska ◽  
Dominik Golicki ◽  
Lidia Groele ◽  
Ewa Pańkowska
Keyword(s):  
Systematic Review ◽  
Type 1 Diabetes ◽  
Insulin Analogue ◽  
Meta Analysis ◽  
Nph Insulin ◽  
Acting Insulin ◽  
Long Acting

scholarly journals Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

Diabetes Care ◽  
2000 ◽  
Vol 23 (5) ◽  
pp. 644-649 ◽  
Author(s):  
L. Heinemann ◽  
R. Linkeschova ◽  
K. Rave ◽  
B. Hompesch ◽  
M. Sedlak ◽  
...  
Keyword(s):  
Insulin Glargine ◽  
Insulin Analog ◽  
Nph Insulin ◽  
Acting Insulin ◽  
Analog Insulin ◽  
Long Acting ◽  
Action Profile

scholarly journals Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

Diabetes Care ◽  
2013 ◽  
Vol 37 (3) ◽  
pp. 659-665 ◽  
Author(s):  
Richard M. Bergenstal ◽  
Julio Rosenstock ◽  
Edward J. Bastyr ◽  
Melvin J. Prince ◽  
Yongming Qu ◽  
...  
Keyword(s):  
Insulin Glargine ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glucose Variability ◽  
Acting Insulin ◽  
Lower Glucose ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document